Rallybio Corporation
NASDAQ:RLYBBiotechnology
+$0.01 today
- Market cap
- $83.56M
- Beta
- -0.88
- P/E (TTM)
- -11.6
- EPS (TTM)
- -$1.37
Volume 0.04M
Average 0.25M
Returns on capital
Rallybio Corporation management
Start with the returns management earns on the capital it controls, then review the people, their trades, and growth quality.
Return Metrics
ROE, ROIC & ROA over time
ROE
-15.5%
avg -52.8%
ROIC
-48.3%
avg -57.6%
ROA
-14.4%
avg -46.7%
Analysis
ROA is currently the strongest return metric at -14.4% versus its period average of -46.7%. 0 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.
Leadership
Who runs the company?
Review the executive team, tenure, compensation, and ownership.
Management
Key executives, compensation & ownership
| Name | Title | Compensation | Age | Shares Owned | Ownership % |
|---|---|---|---|---|---|
Stephen Uden | Co-Founder, President, Chief Executive Officer & Director | USD 857.98K | 68 | 0 | <0.01% |
Jonathan I. Lieber | Chief Financial Officer & Treasurer | USD 645.49K | 56 | 0 | <0.01% |
Martin W. MacKay | Co-Founder & Chairman | USD 290K | 70 | — | — |
Compensation is shown in the reported currency; data updated Nov 7, 2026.
Ownership uses each executive's latest SEC Form 4 holding only when the full name maps to one reporting CIK; latest matched holding Nov 2, 2026.
Insider trading
Are insiders buying or selling?
Follow recent insider purchases and sales reported on Form 4.
Insider Trading
SEC Form 4 transactions — last 12 months
Buys
14
$4.23M
Sells
2
$13,600.30
Net Transaction Value
+$4.22M
Net buying
Most Active
ADAR1 Capital Management, LLC
14 transactions
Transactions sorted by date, descending.
| Type | |||
|---|---|---|---|
| Oct 27, 26Oct 27, 2026 | Lieber Jonathan I Direct | Sell | $9.6K$9,607.96 |
| May 19, 26May 19, 2026 | ADAR1 Capital Management, LLC Indirect | Buy | $2.8K$2,760.00 |
| May 19, 26May 19, 2026 | ADAR1 Capital Management, LLC Indirect | Buy | $139.8K$139,822.00 |
| May 18, 26May 18, 2026 | ADAR1 Capital Management, LLC Indirect | Buy | $84K$83,981.18 |
| May 15, 26May 15, 2026 | ADAR1 Capital Management, LLC Indirect | Buy | $2.8K$2,790.00 |
| May 15, 26May 15, 2026 | ADAR1 Capital Management, LLC Indirect | Buy | $1.4K$1,380.00 |
| May 13, 26May 13, 2026 | ADAR1 Capital Management, LLC Indirect | Buy | $1.1M$1,052,492.00 |
| May 13, 26May 13, 2026 | ADAR1 Capital Management, LLC Indirect | Buy | $56.3K$56,314.94 |
| May 12, 26May 12, 2026 | ADAR1 Capital Management, LLC Indirect | Buy | $11.1K$11,063.04 |
| May 11, 26May 11, 2026 | ADAR1 Capital Management, LLC Indirect | Buy | $278.6K$278,600.00 |
1–10 of 16
Summary
Insiders reported 14 buys worth $4.23M and 2 sells worth $13,600.30 over the last 12 months. That adds up to net buying of $4.22M. ADAR1 Capital Management, LLC was the most active insider with 14 transactions.
Growth analysis
Is management growing the business?
Compare historical growth with analyst forecasts across revenue, earnings, and cash flow.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | N/A | N/A1 analysts |
| Revenue | N/A | N/A | N/A | +219.1% (4yr)1 analysts |
| Net Income | N/A | N/A | N/A | N/A1 analysts |
| EBIT | N/A | N/A | N/A | N/A1 analysts |
Analysis
Forward estimates point to Revenue at +219.1% (4yr), giving you a quick read on expected growth from here.
Competitors
Who does Rallybio Corporation compete with?
Open similar companies to compare how their management teams allocate capital.
Competitors
Peer companies in the same sector
Questions
Management questions
Common questions about RLYB's management, answered from reported figures.
Who manages RLYB?
Rallybio Corporation (RLYB) lists 3 active executives. The top listed executive is Stephen Uden, Co-Founder, President, Chief Executive Officer & Director.
Are RLYB insiders buying or selling?
Recent insider activity shows net buying of $63.08M.
Continue the stock analysis
Jump to another research area for this company.